Clinical trials: Skin Diseases, Bacterial
Acne Vulgaris
Facial Skin Microbiome in Patients With Moderate-to-Severe Acne Vulgaris Treated With Isotretinoin
Acne vulgaris is associated with changes in the facial skin microbiome, but longitudinal microbiome changes during isotretinoin therapy remain incompletely understood.
- Trial name
- FACEMICRO (NCT07834138)
- Testing
- ISOtretinoin 10 MG
- Where
- Vietnam
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Can Tho University of Medicine and Pharmacy
Infection of Skin and/or Subcutaneous Tissue
Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation
The general objective of the study is to assess whether the implementation of the antibiotic essay with the Breakpoint/MIC ratio and data on penetration of the antibiotic in the site of infection may improve the outcome of…
- Trial name
- NCT01551719
- Testing
- Implemented procedure
- Where
- 2 sites in Italy
- Sponsor
- Federico II University
Bacterial Vaginosis, Candidiasis
Vaginal Ecosystem and Network in the United States Study
The central premise of this study is that the intricate balance and diversity of the vaginal microbiome plays a pivotal role in the onset, progression, and severity of various gynecological conditions.
- Conditions
- Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause
- Trial name
- VENUS (NCT06472765)
- Testing
- Vaginal Swab Collection
- Where
- 21 sites in United States, Canada
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Vaginal Biome Science
Candidiasis, Chronic Mucocutaneous
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or…
- Trial name
- CAMB (NCT02629419)
- Testing
- Amphotericin B
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Tinea Cruris, Jock Itch
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
- Trial name
- NCT00750152
- Testing
- NAFT-500
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Chronic Wounds With Different Etiologies
Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay
The objective of this study is to collect wound exudate (fluid) swab samples from Subjects who have wounds that show clinical signs of infection, as well as from Subjects who have wounds that do not show clinical signs of…
- Trial name
- NCT01750203
- Testing
- Swabs
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Systagenix Wound Management
Mild to Moderate Onychomycosis Due to Dermatophyte
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
The antifungal efficacy and safety of Jublia® topical solution will be assessed through an administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due to dermatophyte.
- Trial name
- NCT03280927
- Testing
- Jublia®
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Dong-A ST Co., Ltd.
Dermatomycoses
Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children
Ciclopirox olamine (Ciclochem®) is a pyridone broad spectrum antifungal drug which has shown activity on dermatophytes, yeasts, moulds, actinomycetes and some bacteria.
- Trial name
- NCT01646580
- Testing
- ciclopirox
- Volunteers
- 21 people
- Sponsor
- Ferrer Internacional S.A.
Staphylococcal Skin Infections, Streptococcal Infections
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
The purpose of this study is to characterize the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole after a single…
- Trial name
- NCT01030731
- Testing
- Ceftobiprole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Onychomycosis
Human Factors Testing for OTC Use of the Erchonia® LunulaLaser
Human factors validation testing to assess the intended user's ability to correctly, safely, and effectively set-up, activate and operate the LunulaLaser™ OTC, to administer a treatment to a suitably qualified client, and to…
- Trial name
- NCT05626270
- Testing
- LunulaLaser OTC
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Erchonia Corporation
Hidradenitis Suppurativa
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study.
- Trial name
- NCT01063270
- Testing
- Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Atopic Dermatitis
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
The purpose of the study is the assessment of the barrier impairment, clinical skin condition and bacterial colonization status in patients with atopic eczema following topical treatment with K201 cream and a comparator twice…
- Trial name
- NCT00863005
- Testing
- K201
- Where
- Germany
- Sponsor
- Moberg Pharma AB
Polyendocrinopathies, Autoimmune
Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an autosomal recessive disease caused by mutations in the autoimmune regulator (AIRE) gene, characterized by the clinical triad of chronic mucocutaneous…
- Trial name
- APECED2 (NCT03800056)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Lille
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Hidradenitis Suppurativa
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.
This is a multicenter open-label mode of action study. Twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg Q4W subcutaneously.
- Trial name
- HiGUS (NCT04061395)
- Testing
- Guselkumab
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS1 (NCT00091819)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 862 people
- Sponsor
- Cumberland Pharmaceuticals
Alopecia Areata, Acne Vulgaris
The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia.
The goal of this observational study is to learn about the prevalence and severity of untreated depression and anxiety among adults with skin diseases in Jeddah, Saudi Arabia.
- Conditions
- Alopecia Areata, Acne Vulgaris, Psoriasis, Atopic Dermatitis (Eczema)
- Trial name
- NCT07046039
- Where
- Saudi Arabia
- Volunteers
- 215 people
- Sponsor
- King Abdulaziz University
Leprosy, Buruli Ulcer
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries.
- Conditions
- Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariases
- Trial name
- NCT03683745
- Where
- Liberia
- Volunteers
- 56,285 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Onychomycosis
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel.
- Trial name
- NCT01484145
- Testing
- Terbinafine HCl
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nitric BioTherapeutics, Inc